New combo approach aims to tame transplant complications in bone marrow cancer

This study is for people with myelofibrosis, a type of bone marrow cancer. It tests whether giving a JAK inhibitor drug before, during, and after a half-matched stem cell transplant can lower the risk of graft-versus-host disease (a common complication where donor cells attack the body) without raising the chance of graft failure. About 20 adults aged 18 to 70 with intermediate or high-risk disease will take part.